8-K filing — KORU Medical Systems, Inc. (KRMD)
Filed: 2026-08-14 AccNo: 0001161697-26-000200 Size: 189 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Koru Medical Systems Withdraws 510(K) Application For FreedomEDGE With Phesgo In U.S. To Focus On Alternative Higher Volume Molecules
"Looking ahead for the remainder of 2026, we expect our international core growth to moderate as we navigate regional launch dynamics in specific European markets converting to pre-filled syringes. We remain
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
KORU Medical Systems Narrows FY2026 Sales Guidance from $47.500M-$50.000M to $47.500M-$48.500M vs $48.688M Est
KORU Medical Systems (NASDAQ:KRMD) narrows FY2026 sales outlook from $47.500 million-$50.000 million to $47.500 million-$48.500 million vs $48.688 million estimate.
KORU Medical Systems Q2 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $12.045M Beat $11.609M Estimate
KORU Medical Systems (NASDAQ:KRMD) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 100 percent increase over earnings of $0.01 per share from